{"id":23974,"date":"2021-06-07T15:33:12","date_gmt":"2021-06-07T15:33:12","guid":{"rendered":"https:\/\/www.neuraxpharm.com\/es\/?post_type=scientific-materials&#038;p=23974"},"modified":"2021-06-07T15:33:12","modified_gmt":"2021-06-07T15:33:12","slug":"caso-2-homotaurina-sindrome-dcl","status":"publish","type":"scientific-materials","link":"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl","title":{"rendered":"Caso 2 homotaurina: s\u00edndrome DCL"},"content":{"rendered":"<p>\u00abDeterioro cognitivo ligero y S\u00edndrome de Charles Bonnet\u00bb es el segundo de una serie de cuatro casos cl\u00ednicos con homotaurina en los que se exponen los antecedentes personales, enfermedades, exploraciones neurol\u00f3gicas, pruebas diagn\u00f3sticas y resoluci\u00f3n final del caso.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00abDeterioro cognitivo ligero y S\u00edndrome de Charles Bonnet\u00bb es el segundo de una serie de cuatro casos cl\u00ednicos con homotaurina en los que se exponen los antecedentes personales, enfermedades, exploraciones neurol\u00f3gicas, pruebas diagn\u00f3sticas y resoluci\u00f3n final del caso.<\/p>\n","protected":false},"featured_media":23975,"template":"","categories":[158],"languages":[38],"specialties":[],"country":[26],"class_list":["post-23974","scientific-materials","type-scientific-materials","status-publish","has-post-thumbnail","hentry","categories-demencia","languages-es","country-spain"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Caso 2 homotaurina: s\u00edndrome DCL - Neuraxpharm Espa\u00f1a<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Caso 2 homotaurina: s\u00edndrome DCL\" \/>\n<meta property=\"og:description\" content=\"&quot;Deterioro cognitivo ligero y S\u00edndrome de Charles Bonnet&quot; es el segundo de una serie de cuatro casos cl\u00ednicos con homotaurina en los que se exponen los antecedentes personales, enfermedades, exploraciones neurol\u00f3gicas, pruebas diagn\u00f3sticas y resoluci\u00f3n final del caso.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm Espa\u00f1a\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.neuraxpharm.com\/es\/wp-content\/uploads\/sites\/8\/2021\/06\/caso-2-homotaurina.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1944\" \/>\n\t<meta property=\"og:image:height\" content=\"979\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl\",\"url\":\"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl\",\"name\":\"Caso 2 homotaurina: s\u00edndrome DCL - Neuraxpharm Espa\u00f1a\",\"isPartOf\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl#primaryimage\"},\"thumbnailUrl\":\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/8\/2021\/06\/caso-2-homotaurina.jpg\",\"datePublished\":\"2021-06-07T15:33:12+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl#primaryimage\",\"url\":\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/8\/2021\/06\/caso-2-homotaurina.jpg\",\"contentUrl\":\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/8\/2021\/06\/caso-2-homotaurina.jpg\",\"width\":1944,\"height\":979},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.neuraxpharm.com\/es\/#website\",\"url\":\"https:\/\/www.neuraxpharm.com\/es\/\",\"name\":\"Neuraxpharm Espa\u00f1a\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.neuraxpharm.com\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Caso 2 homotaurina: s\u00edndrome DCL - Neuraxpharm Espa\u00f1a","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl","og_locale":"es_ES","og_type":"article","og_title":"Caso 2 homotaurina: s\u00edndrome DCL","og_description":"\"Deterioro cognitivo ligero y S\u00edndrome de Charles Bonnet\" es el segundo de una serie de cuatro casos cl\u00ednicos con homotaurina en los que se exponen los antecedentes personales, enfermedades, exploraciones neurol\u00f3gicas, pruebas diagn\u00f3sticas y resoluci\u00f3n final del caso.","og_url":"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl","og_site_name":"Neuraxpharm Espa\u00f1a","og_image":[{"width":1944,"height":979,"url":"https:\/\/www.neuraxpharm.com\/es\/wp-content\/uploads\/sites\/8\/2021\/06\/caso-2-homotaurina.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl","url":"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl","name":"Caso 2 homotaurina: s\u00edndrome DCL - Neuraxpharm Espa\u00f1a","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl#primaryimage"},"image":{"@id":"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl#primaryimage"},"thumbnailUrl":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/8\/2021\/06\/caso-2-homotaurina.jpg","datePublished":"2021-06-07T15:33:12+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.neuraxpharm.com\/es\/medico\/materiales-cientificos\/caso-2-homotaurina-sindrome-dcl#primaryimage","url":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/8\/2021\/06\/caso-2-homotaurina.jpg","contentUrl":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/8\/2021\/06\/caso-2-homotaurina.jpg","width":1944,"height":979},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/es\/#website","url":"https:\/\/www.neuraxpharm.com\/es\/","name":"Neuraxpharm Espa\u00f1a","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/scientific-materials\/23974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/scientific-materials"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/types\/scientific-materials"}],"version-history":[{"count":2,"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/scientific-materials\/23974\/revisions"}],"predecessor-version":[{"id":24009,"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/scientific-materials\/23974\/revisions\/24009"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/media\/23975"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/media?parent=23974"}],"wp:term":[{"taxonomy":"categories","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/categories?post=23974"},{"taxonomy":"languages","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/languages?post=23974"},{"taxonomy":"specialties","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/specialties?post=23974"},{"taxonomy":"country","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/es\/wp-json\/wp\/v2\/country?post=23974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}